XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales $ 3,540 $ 3,926  
Selling, general and administrative 2,483 2,479  
Research and development 3,992 4,276  
Other current assets 31,445   $ 32,168
Accrued and other current liabilities 14,102   15,766
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 330 298  
Cost of sales 82 70  
Selling, general and administrative 39 47  
Research and development 20 21  
Other current assets 334   341
Accrued and other current liabilities 617   256
Other noncurrent liabilities 0   $ 600
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 292 275  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement $ 38 $ 23